Contact
searchSearch
HMP Global

Biosimilars Topic Center

Industry Insights
News Conference Coverage
Expert Perspectives
Videos Podcasts
Issue Content
Managed Care Q&A

news


News
Biosimilars Gain Market Traction but Adoption Varies by Demographics and Other Factors
03/18/2025
Biosimilars are gaining market share and reducing drug costs, but patient adoption varies based on demographics, care settings, and payer policies.
Biosimilars are gaining market share and reducing drug costs, but patient adoption varies based on demographics, care settings, and payer policies.
Biosimilars are gaining market...
03/18/2025
First Report Managed Care
News
Unlocking Cost-Efficiency and Access With Biosimilar Bevacizumab in Medicare
03/13/2025
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant...
03/13/2025
First Report Managed Care
News
Shifting Trends in Trastuzumab Utilization As Biosimilar Adoption Increases
03/05/2025
The use of trastuzumab for treating breast and other cancers has declined as trastuzumab biosimilars gain widespread adoption in the US.
The use of trastuzumab for treating breast and other cancers has declined as trastuzumab biosimilars gain widespread adoption in the US.
The use of trastuzumab for...
03/05/2025
First Report Managed Care
News
Biosimilar Adalimumab Adoption Could Yield Millions in Cost Savings, Study Finds
02/20/2025
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals...
02/20/2025
First Report Managed Care
News
IQVIA Report Highlights Growing ‘Biosimilar Void’ as Biologic Patent Expiries Accelerate
02/13/2025
A new report by the IQVIA Institute warns that a growing "biosimilar void" could cost the US health care system billions in missed savings as biologic patent expirations accelerate over the next decade.
A new report by the IQVIA Institute warns that a growing "biosimilar void" could cost the US health care system billions in missed savings as biologic patent expirations accelerate over the next decade.
A new report by the IQVIA...
02/13/2025
First Report Managed Care
News
Differences in Post-Induction Levels and Response Rates Between Crohn's Disease and Ulcerative Colitis Medications
02/06/2025
A comparison of infliximab brands Inflectra and Remsima in patients with Crohn's disease and ulcerative colitis reveals differences in post-induction levels and response rates, suggesting potential considerations for dosing adjustments based...
A comparison of infliximab brands Inflectra and Remsima in patients with Crohn's disease and ulcerative colitis reveals differences in post-induction levels and response rates, suggesting potential considerations for dosing adjustments based...
A comparison of infliximab...
02/06/2025
First Report Managed Care
News
Biosimilar Competition Reduces Adalimumab Spending but Faces Challenges in Uptake
01/20/2025
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar...
01/20/2025
First Report Managed Care
News
Biosimilars Expand Access and Cut Costs in HER2-Positive Cancer Treatment
01/10/2025
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of...
01/10/2025
First Report Managed Care
News
Provider Perceptions of Biosimilar Use in Oncology Networks
01/03/2025
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the...
01/03/2025
First Report Managed Care
News
Oncology Biosimilars Offer Cost-Efficient Solutions for Sustainable Health Care
12/19/2024
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have...
12/19/2024
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

Conference Coverage
The Impact of Fatigue on Prospective Memory in Persons With MS
05/23/2024
High fatigue levels in persons with multiple sclerosis (MS) are significantly associated with subjective impairment in prospective memory, particularly in tasks such as forgetting the date and missing appointments.
High fatigue levels in persons with multiple sclerosis (MS) are significantly associated with subjective impairment in prospective memory, particularly in tasks such as forgetting the date and missing appointments.
High fatigue levels in persons...
05/23/2024
First Report Managed Care
Interview
Enhancing Patient Services: Payer and Provider Considerations
06/28/2024
Patient services emerged as a central topic at AXS24, with many stakeholders emphasizing the need for consistency and accessibility in patient support. They also highlighted the importance of addressing both financial and emotional support...
Patient services emerged as a central topic at AXS24, with many stakeholders emphasizing the need for consistency and accessibility in patient support. They also highlighted the importance of addressing both financial and emotional support...
Patient services emerged as a...
06/28/2024
First Report Managed Care
Poll
Opinions on RSV Mutations
07/29/2024
Are you concerned about the impact of RSV mutations on the effectiveness of current therapeutics in preventing the virus from spreading?
Are you concerned about the impact of RSV mutations on the effectiveness of current therapeutics in preventing the virus from spreading?
Are you concerned about the...
07/29/2024
First Report Managed Care
News
Study Finds Gemcitabine-Docetaxel Combo Outperforms BCG in Treating High-Risk Bladder Cancer
08/23/2024
Gemcitabine and docetaxel therapy may be a viable alternative to bacillus Calmette-Guérin (BCG) for patients with high-risk non-muscle invasive bladder cancer (NMIBC), according to study results published in JAMA Network Open.
Gemcitabine and docetaxel therapy may be a viable alternative to bacillus Calmette-Guérin (BCG) for patients with high-risk non-muscle invasive bladder cancer (NMIBC), according to study results published in JAMA Network Open.
Gemcitabine and docetaxel...
08/23/2024
First Report Managed Care
Conference Coverage
How AI is Revolutionizing Rare Disease Diagnosis and Treatment Despite Lack of Diversity in Patient Populations
09/23/2024
AI has the potential to revolutionize the diagnosis and treatment of rare diseases, but challenges in patient diversity are being addressed through cross-border collaboration and engagement with patient communities.
AI has the potential to revolutionize the diagnosis and treatment of rare diseases, but challenges in patient diversity are being addressed through cross-border collaboration and engagement with patient communities.
AI has the potential to...
09/23/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use